Compare AbbVie Inc (ABBV) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ING Groep NV — how do they compare? AbbVie Inc trades at $252.23 (market cap $449.91B), while ING Groep NV trades at $31.94 (market cap $92.35B). The key difference: AbbVie Inc is far larger — about 4.9× ING Groep NV's market cap, and ING Groep NV pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ABBV | ING | |
|---|---|---|
Market Cap | $449.91B | $92.35B |
Sector | Health | Financials |
52-Week High | $261.07 | $32.96 |
52-Week Low | $184.85 | $22.45 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.65, down 0.04% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $3.79. Recent positive Phase 2 data for ELAHERE in ovarian cancer and strong institutional buying activity highlight growth momentum. Valuation metrics appear elevated with a P/E of 124.83 and P/B of 245.29, though the company maintains a robust gross margin of 70.68% and consistent dividend payments.
The outlook remains positive with analyst consensus at 'Buy' and a $266.33 price target, representing 4.6% upside. Key opportunities include Skyrizi and Rinvoq growth offsetting Humira declines, while risks include high debt levels, patent cliffs in the 2030s, and elevated valuation multiples that could pressure returns if growth slows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
